Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) was discovered almost 40 years ago [1–3] and the first AAV vectors were described 20 years ago [4–6], which led to initiation of the first human clinical trial of an AAV vector some 8 years ago, in cystic fibrosis patients [7]. These events also delineate three periods in the history of AAV vector development. In the first 20 years, the basic elements of the AAV genome structure, growth cycle, and latency were described. In the early 1980s, infectious molecular clones of AAV serotype 2 were generated and the AAV2 DNA sequence was determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
Samulski, R. J., Berns, K. I., Tan, M., & Muzyczka, N. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2077 · Cited by 466
Adeno-associated virus general transduction vectors: analysis of proviral structures
McLaughlin, S. K., Collis, P., Hermonat, P. L., & Muzyczka, N. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1963-1973.1988 · Cited by 348
Samulski, R. J., Srivastava, A., Berns, K. I., & Muzyczka, N. (1983) · Cell · doi:10.1016/0092-8674(83)90342-2 · Cited by 297
Cloning of infectious adeno-associated virus genomes in bacterial plasmids
Laughlin, C. A., Tratschin, J.-D., Coon, H., & Carter, B. J. (1983) · Gene · doi:10.1016/0378-1119(83)90217-2 · Cited by 266
Self-citationGenetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle
Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A., & Johnson, P. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3495-3504.2003 · Cited by 262
Tratschin, J. D., West, M. H., Sandbank, T., & Carter, B. J. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.10.2072 · Cited by 202
Self-citationStraus, S. E., Sebring, E. D., & Rose, J. A. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.3.742 · Cited by 194
Rose, J. A., Berns, K. I., Hoggan, M. D., & Koczot, F. J. (1969) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.64.3.863 · Cited by 179
Assembly of adeno-associated virus
Myers, M. W., & Carter, B. J. (1980) · Virology · doi:10.1016/0042-6822(80)90071-9 · Cited by 107
Self-citation
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Aschauer, D. F., Kreuz, S., & Rumpel, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076310 · Cited by 522
“AAV is a single-stranded DNA virus with a small (~20nm) protein capsule that belongs to the family of parvoviridae [6,7].”
BackgroundGene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
Recent Advances in CRISPR/Cas9 Delivery Strategies
Yip, B. (2020) · Biomolecules · doi:10.3390/biom10060839 · Cited by 292
Bish, L. T., Morine, K., Sleeper, M. M., Sanmiguel, J., Wu, D., Gao, G., Wilson, J. M., & Sweeney, H. L. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.123 · Cited by 292
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Moss, R. B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P. L., Clancy, J. P., Spencer, L. T., Pilewski, J., Waltz, D. A., Dorkin, H. L., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.022 · Cited by 277
Self-citationEvidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb
Lai, Y., Yue, Y., & Duan, D. (2010) · Molecular Therapy · doi:10.1038/mt.2009.256 · Cited by 166
Roska, B., & Sahel, J.-A. (2018) · Nature · doi:10.1038/s41586-018-0076-4 · Cited by 161
Adeno-Associated Virus Biology
Weitzman, M. D., & Linden, R. M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_1 · Cited by 132
De, B. P., Heguy, A., Hackett, N. R., Ferris, B., Leopold, P. L., Lee, J., Pierre, L., Gao, G., Wilson, J. M., & Crystal, R. G. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.003 · Cited by 129
“Use of Nonhuman Primate AAV Serotypes as Gene Transfer Vectors AAV-based vectors are useful for gene transfer because of their low toxicity and persistent transgene expression levels [34–41].”
AAV transcytosis through barrier epithelia and endothelium
Di Pasquale, G., & Chiorini, J. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.007 · Cited by 121
Schwartz, R. A., Carson, C. T., Schuberth, C., & Weitzman, M. D. (2009) · Journal of Virology · doi:10.1128/jvi.00318-09 · Cited by 115
Recombinant Adeno-Associated Viral Vectors in the Nervous System
Burger, C., Nash, K., & Mandel, R. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.781 · Cited by 110
Schnödt, M., & Büning, H. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.188 · Cited by 77
Adeno-associated Virus: A Key to the Human Genome?
Henckaerts, E., & Linden, R. M. (2010) · Future Virology · doi:10.2217/fvl.10.48 · Cited by 71
“5 kb, which is unable to replicate or integrate site specifically as it is missing the viral proteins necessary to direct these events [18].”
BackgroundRational engineering of a functional CpG-free ITR for AAV gene therapy
Pan, X., Yue, Y., Boftsi, M., Wasala, L. P., Tran, N. T., Zhang, K., Pintel, D. J., Tai, P. W. L., & Duan, D. (2022) · Gene Therapy · doi:10.1038/s41434-021-00296-0 · Cited by 53
Okada, T., Uchibori, R., Iwata-Okada, M., Takahashi, M., Nomoto, T., Nonaka-Sarukawa, M., Ito, T., Liu, Y., Mizukami, H., Kume, A., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.010 · Cited by 51
“Recombinant adeno-associated virus (rAAV) has been of considerable interest to developers of clinical gene therapies [1,2].”
BackgroundOcular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
“Adeno-associated viruses (AAVs) were originally discovered in the mid-1960s as satellite viruses associated with adenoviruses, hence the name ‘adeno-associated’ [10].”
BackgroundGenome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction
Mano, M., Ippodrino, R., Zentilin, L., Zacchigna, S., & Giacca, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503607112 · Cited by 39
Synthetic Intron Improves Transduction Efficiency of Trans -Splicing Adeno-Associated Viral Vectors
Lai, Y., Yue, Y., Liu, M., & Duan, D. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1036 · Cited by 37
“ASSOCIATED VIRUS (AAV) has been adapted as one of the most effective gene delivery ve-Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO 65212. hicles (Carter, 2004; Flotte and Berns, 2005; Gao et al ., 2005).”
McAlister, V. J., & Owens, R. A. (2010) · Virology Journal · doi:10.1186/1743-422x-7-218 · Cited by 5
Metadata
- Authors
- Carter, B. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2004-12
- Volume
- 10
- Issue
- 6
- Pages
- 981-989
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2049735665
- Cited by
- 157
- References
- 12
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.